MA44737A - Compositions pour le traitement de troubles liés à l'hyperkératose - Google Patents

Compositions pour le traitement de troubles liés à l'hyperkératose

Info

Publication number
MA44737A
MA44737A MA044737A MA44737A MA44737A MA 44737 A MA44737 A MA 44737A MA 044737 A MA044737 A MA 044737A MA 44737 A MA44737 A MA 44737A MA 44737 A MA44737 A MA 44737A
Authority
MA
Morocco
Prior art keywords
hyperkeratosis
compositions
treatment
disorders related
disorders
Prior art date
Application number
MA044737A
Other languages
English (en)
Inventor
Yair Alster
Shimon Amselem
Doron Friedman
Zakhar Nudelman
Omer Rafaeli
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of MA44737A publication Critical patent/MA44737A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA044737A 2016-04-19 2017-04-18 Compositions pour le traitement de troubles liés à l'hyperkératose MA44737A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662324795P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
MA44737A true MA44737A (fr) 2021-04-07

Family

ID=60115757

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044737A MA44737A (fr) 2016-04-19 2017-04-18 Compositions pour le traitement de troubles liés à l'hyperkératose

Country Status (10)

Country Link
US (2) US20200179305A1 (fr)
EP (1) EP3445352A4 (fr)
JP (1) JP2019513775A (fr)
KR (1) KR20180133913A (fr)
CN (1) CN109328061A (fr)
AU (1) AU2017252026A1 (fr)
CA (1) CA3020713A1 (fr)
IL (1) IL262348A (fr)
MA (1) MA44737A (fr)
WO (1) WO2017182885A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CN108472312A (zh) 2015-09-28 2018-08-31 阿祖拉眼科有限公司 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂
MA44676A (fr) 2016-04-14 2019-02-20 Azura Ophthalmics Ltd Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
MX2019004263A (es) 2016-10-12 2019-09-18 Jds Therapeutics Llc Composiciones de picolinato de magnesio y metodos de uso.
CN108840904B (zh) * 2018-07-12 2022-03-04 江西中科硒谷功能农业发展有限公司 一种从烟叶中提取硒蛋白质的方法
JP7142286B2 (ja) * 2018-07-13 2022-09-27 慶應義塾 セレン含有アミノ酸を含む糖鎖－ポリペプチド複合体、および、その医薬用途
KR20220003555A (ko) 2019-04-18 2022-01-10 아주라 오프탈믹스 엘티디 안구 장애의 치료를 위한 화합물 및 방법
CA3137583A1 (fr) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Composes et procedes pour le traitement de troubles oculaires
EP3955937A4 (fr) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. Composés et procédés pour le traitement de troubles oculaires
US20200345768A1 (en) * 2019-05-01 2020-11-05 Nutrition 21, Llc Zinc picolinate, magnesium picolinate and selenium methionine compositions and methods of use
EP4087655A4 (fr) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd Instructions pour composition et sensibilité
CN116635032A (zh) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
US6495158B1 (en) * 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
US20030224028A1 (en) * 2002-05-13 2003-12-04 Societe L'oreal S.A. Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
CA2556503A1 (fr) * 2004-02-19 2005-09-01 Occell Inc. Formulations topiques pour le traitement d'etats dermatologiques
PL1791423T3 (pl) * 2004-08-02 2013-09-30 Sami Labs Ltd Kompozycje i sposoby postępowania z hiperproliferacyjnymi zaburzeniami dermatologicznymi
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
AU2006260184B2 (en) * 2005-06-22 2011-05-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Prophylactic or therapeutic agent for corneal/conjunctival disease
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
KR102134938B1 (ko) * 2012-12-21 2020-07-17 아쿠아 바이오 테크놀로지 에이에스에이 어류 부화액으로부터의 화장료 조성물
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction

Also Published As

Publication number Publication date
US20200179305A1 (en) 2020-06-11
EP3445352A2 (fr) 2019-02-27
AU2017252026A1 (en) 2018-11-08
CN109328061A (zh) 2019-02-12
US20230013824A1 (en) 2023-01-19
WO2017182885A3 (fr) 2017-12-14
IL262348A (en) 2018-11-29
CA3020713A1 (fr) 2017-10-26
JP2019513775A (ja) 2019-05-30
KR20180133913A (ko) 2018-12-17
WO2017182885A2 (fr) 2017-10-26
EP3445352A4 (fr) 2019-12-11

Similar Documents

Publication Publication Date Title
MA44737A (fr) Compositions pour le traitement de troubles liés à l&#39;hyperkératose
MA49279A (fr) Compositions d&#39;anticorps optimisées pour le traitement de troubles oculaires
EP3423047A4 (fr) Compositions d&#39;agonistes sélectifs du récepteur cb2 pour le traitement des troubles mentaux
EP3558313A4 (fr) Substances pour le traitement d&#39;affections liées à la stéatose hépatique
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d&#39;infections virales
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
MA44083A (fr) Composés de biarylmonobactame pour le traitement d&#39;infections bactériennes
EP3465212A4 (fr) Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3630102A4 (fr) Formulations pour le traitement d&#39;un trouble de stress post-traumatique
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3541408A4 (fr) Compositions et méthodes pour le traitement de l&#39;angiogenèse aberrante
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3634426A4 (fr) Compositions pour le traitement d&#39;une fibrose
EP3541379A4 (fr) Compositions pour le traitement de l&#39;hypertension
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l&#39;asthme
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
EP3716966A4 (fr) Compositions d&#39;alpha-cétoacides pour le traitement de l&#39;hypoalbuminémie
EP3612214A4 (fr) Optimisation d&#39;enzymothérapie de remplacement pour le traitement de l&#39;homocystinurie
EP3773221A4 (fr) Traitement pour l&#39;hydrocéphalie